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ABSTRACT An Electronic Medical Record (EMR) is a professional document that contains all data 
generated during the treatment process. The EMR can utilize various data formats, such as numerical data, 
text, and images. Mining the information and knowledge hidden in the huge amount of EMR data is an 
essential requirement for clinical decision support, such as clinical pathway formulation and evidence-based 
medical research. In this paper, we propose a machine-learning-based framework to mine the hidden 
medication patterns in EMR text. The framework systematically integrates the Jaccard similarity 
evaluation, spectral clustering, the modified Latent Dirichlet Allocation and cross matching among multiple 
features to find the residuals that describe additional knowledge and clusters hidden in multiple 
perspectives of highly complex medication patterns. These methods work together step by step to reveal the 
latent medication pattern. We evaluated the method by using real data from EMR text (patients with 
cirrhotic ascites) from a large hospital in China. The proposed framework outperforms other approaches for 
medication pattern discovery, especially for this disease with subtle medication treatment variances. The 
results also revealed little overlap among the discovered patterns; thus, the distinct features of each pattern 
are well studied through the proposed framework. 
INDEX TERMS Electronic Medical Record (EMR); medication pattern; discovery; machine learning; 
high-complexity drug-use pattern 
I. INTRODUCTION 
Evidence-based medicine is recognized as an imperative 
approach to optimize decision-making in medical practice 
[1]. In the past, the evidence mainly came from well-
designed, well-conducted clinical trials and the validated 
personal experiences of physicians. The most reliable 
evidence-based medicine is based on randomized controlled 
trials designed for large populations of patients [2]. 
However, the increasing number of clinical and biological 
parameters that must be collected for precision medicine 
make it almost impossible to design dedicated trials [3]. A 
Medical Record (MR), which was a paper document in the 
past and now is mostly computerized, is the systematic 
documentation of a patient's medical care history across 
time within one particular health care provider's jurisdiction 
[4]. Namely, MRs can be seen as the logs that describe 
patients’ treatments and other hospital activities with 
outcomes, such as recovery, transfer and death. 
As the most important medical log documenting patients’ 
whole treatment processes and evolving statuses, Electronic 
Medical Records (EMR) contain rich clinical data, 
information and knowledge. Furthermore, the amount of 
EMR data has been rapidly increasing with the hospital 
digitalization process. From the view of evidence-based 
medicine, EMRs are the best clinical evidence of positive 
(i.e., recovery) or negative (i.e., death) treatment results. 
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EMRs also have great potential for enabling data-driven 
predictions and further explorations of clinical knowledge if 
the EMR data can be deeply analyzed. The mining outcomes 
are helpful to support physicians’ decisions during patients’ 
journeys [5]-[7], such as treatment pathway personalization. 
Recent studies [8]-[10] show that machine-learning methods 
are important and powerful EMR-analyzing technologies that 
can mine the underlying knowledge [8]-[10]. 
In this research, we aimed to discover medication 
patterns from highly complex drug treatments and diseases 
by systematically applying Jaccard similarity, spectral 
clustering, and Bayes probability techniques for EMR text 
mining. Cirrhotic ascites EMR data were selected to 
evaluate our approach since patients with this disease 
always have many complications and require complex 
medication patterns [11]. Our approach outperformed other 
machine-learning-based methods in the following aspects. 
1) The approach effectively discovered the major 
medication patterns from EMR text for highly complex 
diseases and mixed medication patterns. 2) This approach 
can separate the highly mixed medication treatments into 
distinct clustered medication patterns rather than vague 
future clustering that classifies every item into one of the 
treatment patterns, although the similarity was weak. 3) 
Unlike unsupervised deep-learning-based treatment pattern 
discovery methods, our classification approach results in 
each step of the framework being interpretable rather than a 
black box [12]. This approach is important for clinical 
knowledge discovery (since it is evidence based and 
interpretable) to understand the classifying processes of 
certain drugs for clinical purposes. 4) To the best of our 
knowledge, this is the first time machine learning methods 
have been used for medication discovery from cirrhotic 
ascites EMRs. 
The rest of this paper is organized as follows. Section II 
is the review of related works. Section III describes the 
proposed framework and methods to discover latent 
medication patterns. Section IV presents the real data 
experiments and discussions followed by the conclusions in 
the last section. 
II. RELATED WORKS 
EMR text mining is a systematic project that includes data 
extraction and mining from textual EMR sources (with a 
focus on the mining part) to discover meaningful knowledge. 
Similar to an EMR, an Electronic Health Record (EHR) is 
also a medical record, but it places emphasis on daily data 
across hospitals, social care and self-reported/monitored data 
for long-term health status. Therefore, this section provides a 
state-of-the-art review on both EMR and EHR textual data 
processing and mining research. 
A. EMR TEXT PRE-PROCESSING 
It has been a challenging task to analyze the textual content 
of EMRs in current research [13]. Existing research has 
adopted the Natural Language Processing (NLP) technique 
that focuses on targeting and extracting useful information 
from EMRs for clinical research [14]-[18]. The 
International Classification of Diseases (ICD) and the 
Systematized Nomenclature of Medicine-Clinical Terms 
(SNOMED-CT) are two widely adopted medical term sets 
and powerful tools in medical semantics analytics. These 
coding systems play important roles in targeting specific 
words or segmentations within EMR text. However, those 
standardized terms are not always mandatory in EMR 
records. Some studies [15], [16], [19], [20] use multiple 
lexicon databases to cover a wide range of words and/or 
phrases to create their own dictionaries. Another challenge 
in processing Chinese EMRs is that there is no official 
Chinese SNOMED-CT available, while English EMR text 
mining is relatively easier since every word in a sentence is 
separated by spaces. Spaces help to improve the precision 
of information segmentation in text mining, but Chinese 
sentences are made up of characters with no spaces between 
words [21]. Some authors [22]-[24] have attempted Chinese 
EMR text mining based on a special lexicon or a manually 
established ontology structure. Some meaningful results 
have been discovered from those approaches, but they 
require significant manual work to process the textual data. 
Although word segmentation in Chinese characters is a 
challenging task, it is a prerequisite step to directly mine 
information and knowledge from EMR text. 
In this study, we focused on mining clinical knowledge 
from EMR text with a hybrid text-preprocessing approach. 
To segment Chinese text in EMRs, we first selected the 
medical terms with Chinese ICD codes. Then, we used a 
word dictionary from existing hospital information systems 
and further created the dictionary for this research. The aim 
of EMR text pre-processing is to extract meaningful words 
and information from the text in order to provide the 
computer readable data for subsequent processing. 
B. EMR/EHR DATA MINING 
The deep learning approach has attracted significant 
attention in data representation and prediction from high 
dimensional EMR data. Reference [25] proposed a deep 
multi-modality architecture for EHR analysis based on 
Poisson Factor Analysis modules. This architecture is able 
to identify Type 2 Diabetes Mellitus (T2DM) patients from 
a group of all kinds of patients using diagnosis codes and 
laboratory tests. Reference [26] presented Deepr (short for 
Deep record), a new end-to-end deep learning system, that 
learns to automatically extract features from medical 
records and predict future risks. Reference [27] proposed a 
deep learning approach for phenotyping from patient EHRs. 
Existing deep learning approaches always focus on disease 
prediction or identification based on EMR/EHR non-picture 
data, such as the work of [28]-[30]. However, in 
unsupervised deep learning cases, the accuracy varies due 
to the lack of consideration of uncertainties in complex 
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diseases. Furthermore, deep learning as a black box with 
obscure reasoning processes has limited its capability of 
supporting clinical research. Our proposed framework aims 
to discover hidden patterns that are normally omitted in 
high-complexity medication diseases and give more 
semantics and interpretability to identified patterns. 
Traditional machine learning methods (e.g., non-deep 
learning methods) are also powerful tools for mining 
knowledge from EMR data. Reference [31] demonstrates a 
framework for identifying subjects with and without T2DM 
from EHRs with relatively high accuracy and performance. 
This framework integrates several machine learning 
methods, such as the k-Nearest-Neighbors, Naïve Bayes, 
Decision Tree, Random Forest, Support Vector Machine 
and Logistic Regression. Based on k-means clustering and 
EMR data, Rajkomar et al. [32] characterized the utilization 
patterns of primary care patients and created weighted 
panel sizes for providers based on the work required to care 
for patients with different patterns. Reference [19] 
classified obesity and obesity types in thousands of EMRs 
by using the Support Vector Machine (SVM) and Naïve 
Bayes models, and the experimental results indicate that the 
SVM performs better. Reference [33] proposed a flexible 
hierarchical Bayesian nonparametric model to cluster 
medical data into groups. This work was inspired by the 
structure of ICD codes that can present semantic 
relationships between different diseases. Similarly, an 
improved Latent Dirichlet allocation (LDA) model [34] that 
is also a probabilistic model was applied to discover the 
changing trends of medical behaviors over time from 
EMRs. The above machine learning models provide 
effective ways to mine knowledge from EMRs. However, 
they are context sensitive, since the same model always has 
different results in different EMR mining scenarios. These 
models require more robustness. 
Following the LDA model, Reference [35]-[37] proposed 
the latent treatment pattern discovery model based on the 
treatment logs to analyze the EMRs of cardiovascular and 
cerebrovascular diseases. Although the temporal 
dimensions are important in clinical practice, the LDA has 
limited capability of identifying the time sequence of 
treatment activities from the medical logs. To solve this 
problem, Reference [36]-[37] used the tuple <timestamp, 
activity> to identify a single treatment activity in the LDA 
model. In this paper, we discovered medication patterns 
from EMRs in hepatocirrhosis ascites diseases. The pure 
LDA model could not adequately identify the medication 
patterns for hepatocirrhosis ascites. Since there are many 
complexities among treatments for different patients with 
this disease, the medication treatments for some patients 
always have subtle variances, and drug uses are always 
highly mixed. Moreover, traditional LDA-based methods 
cannot compare the relative importance of the treatment 
between different patient groups/patterns. According to the 
real data test in the following section of this paper, the 
proposed framework and methods effectively discovered 
the distinct medication patterns with minor differences for 
this disease with highly complex medication patterns. 
Furthermore, the time-density-reduction method can 
support the relative importance of the same drug in 
different medication patterns. 
III. FRAMEWORK AND METHOD TO DISCOVER 
LATENT MEDICATION PATTERNS 
A. GENERAL METHOD TO DISCOVER THE 
MEDICATION PATTERN 
Generally, four steps are needed to discover treatment 
patterns in EMR text, as shown in Figure 1. These steps 
include data extraction, data pre-processing for 
classification, medication data clustering and medication 
pattern recognition. 
In the first step, the challenge lies in precisely extracting 
meaningful data from the EMR text. An EMR is a kind of 
professional and technical document written by physicians 
in a natural language. Therefore, the key question is where 
to cut or split a sentence into meaningful words and 
phrases. In the English language, two words are separated 
by spaces. However, there are no spaces in Chinese 
sentences to separate words. Thus, the effectiveness of 
word segmentation determines the accuracy of the data 
extracted from EMRs. In the second step, the extracted data 
in the form of numbers, words and phrases are transformed 
into a format that the computer can process, such as a word 
matrix. In the third step, a medication data framework 
classifies the extracted drugs into different groups. 
However, in order to reveal the clinical meaning from the 
clustered data, the fourth step recognizes the medication 
pattern. 
Based on the general process above, we developed a 
hybrid medication pattern discovery method by introducing 
the LDA model and the special clustering algorithm. Figure 
2 describes the mining process that will be elaborated upon 
in the subsequent section. 
B. BASIC PROCESSING STEPS 
Data segmentation and extraction is the basic processing 
step that begins the mining process. Although Chinese is 
slightly different from English in an NLP analysis, 
extracting drug use situations is easier than extracting other 
elements (i.e., the description of an illness) in EMR free 
text. This is because the name of the drug is stable and 
consistent. To extract Chinese drug treatment content from 
EMR text, we used a medicine dictionary provided by our 
collaborative hospital to extract the names of drugs. 
Following the names of drugs in EMR text, there are usage 
instructions, such as the specific drug usage time and 
duration. We used key words to automatically extract this 
information. Figure 3 shows an example that extracts 
necessary data from EMR text. In this example, red words 
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(English) / characters (Chinese) are key words that can be used to locate corresponding information in the sentence. 
The drug name can be extracted from the sentences using a 
dictionary. 
C. PATTERN DISCOVERY WITHOUT TIME SEQUENCE 
1) REPRESENT THE MEDICATION TREATMENT OF 
PATIENTS WITH A P-M MATRIX 
Based on the extracted data from EMRs, we used a two-
dimensional matrix to represent the medication process for 
each patient. Columns of the matrix indicate the day of the 
treatment in the hospital, and each line indicates a drug. 
Assume  is a P-D (Patient-Drug) matrix of patient , and 
ijis an element in . Then, ij=1 if this patient used drug i 
on the jth day, and otherwise ij=0. 
Note that the size of these matrices may be different since 
different patients may have different lengths of stay (LoSs). 
Figure 4 gives two medication matrices with different sizes 
for Patient x and Patient y, where the LoS is 10 days and 12 
days for Patient x and Patient y, respectively. 
The size discrepancy of the P-D matrix has increased the 
challenge of comparing the similarities among matrices. 
Although the P-D matrix is an important way to represent 
and store the medication process, it is difficult to directly 
cluster the medication treatments of different patients using 
the P-M matrix. One possible way is to drop the time 
information from the matrix when calculating the similarity 
and clustering of the medication patterns. In the following 
steps, we clustered the medication cases without 
considering timestamps. 
2) MEASURE THE SIMILARITY OF PRESCRIBED 
MEDICATIONS WITH THE JACCARD SIMILARITY 
COEFFICIENT 
Similarity is an important factor that can cluster patients 
with similar medication treatments. To measure the 
similarity of the medication experiences of patients who 
have different LoSs, the Jaccard index [38] is introduced, 
and the time information is dropped. The Jaccard similarity 
coefficient J is defined as equation (1): 
| |
( , )
| |
A B
J A B
A B
    (1) 
where A and B are sample sets. The definition can be 
understood as the size of the intersection divided by the size 
of the union of the sample sets. The similarity of sets A and B 
can be acquired by (2). 
| | | |
( , ) 1 ( , )
| |
d
A B A B
J A B J A B
A B

     (2) 
in which Jd (the Jaccard Distance) is the distance between A 
and B. 
According to equations (1) and (2), we calculated the 
similarity of medication treatments of different patients based 
on a P-M matrix. A Patient-Patient Matrix (P-P Matrix) can 
describe the similarity degree. For illustration, we extracted 
part of the patients into a P-P Matrix PJ shown in (3), which 
included 20 patients. 
20*20
46.2 13 26.7 18.8 20 22.6 3.8 13.5 16.7 9.1 14.3 17.6 26.9 19.4 14.8 27.6 21.1 20.61 24
13 18.8 15.2 25 18.8 3.8 20 17.1 18.5 25 22.2 16.2 19.2 23.3 17.9 24.2 19.21 14
23.8 18.2 10 15.6 2.5 19.1 23.5 19.2 12.2 25.6 23.7 16.3 20.6 13.3 17.6 27.1
PJ 
9 15.4
31 11.1 22.6 0 16.7 16.7 9.1 14.3 14.3 43.5 22.9 14.8 23.3 27.8 20.61 24
20 35.7 3.8 27.3 19.5 6.7 23.1 17.6 43.5 26.5 19.2 27.6 27.8 20.61 24
20 0 21.4 7.9 11.1 33.3 23.1 19 12.9 12.5 26.1 15.2 22.2 21.11
3.8 31.3 25.6 11.6 18.5 17.6 32 26.5 17 321 .1 27.8 24.2 29.2
3.3 2.7 5.7 0 0 0 3.2 2.9 0 01 2 4
26.2 20.9 16.1 29.4 23.3 20.5 24.5 24.2 31.6 32.4 20.71
37.2 10.3 21.4 25.7 22.7 32.7 23.1 26.7 30 16.71
7.7 10.3 10.4 26.3 9.3 14.3 18.6 5.11 22
25.9 28.6 27.6 14.3 17.6 25 191 24
25 21.6 28 21.9 23.1 48.1 3 22.2
46.2 21.3 33.3 36.7 33.3 36.81
24.1 31.3 34.2 27.8 33.31
27.1 27.3 32.7 171
36.4 33.3 501
32.4 25.81
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(3) 
It can be seen that an adjacent matrix (3) is symmetric, and 
each element pjab in PJ indicates the medication similarity 
between patient a and patient b. 
3) CLUSTER THE PATIENTS WITH SPECTRAL 
CLUSTERING 
Based on the similarity measurement, we can obtain a graph, 
PG, where all of the patients are connected with each other 
under certain edge weights. The weight value is the similarity 
between two patients. Now, the problem of clustering these 
patients can be solved by cutting the graph into several sub-
graphs. Each of the sub-graphs represents a patient cluster in 
which the patients probably have similar medication 
treatments. 
During patient clustering, the aim of cutting is to minimize 
the weights of the connection between two sub-graphs while 
the weights of the connections inside the sub-graphs are high. 
Thus, we introduced a special clustering model called 
Normalized Cut (N-cut) [39]. Considering the connection 
between the relative density of each group, an N-cut (Ncut) 
can be described as (4): 
( , ) ( , )
( , )
( ) ( )
cut C D cut C D
Ncut C D
vol C vol D
   (4) 
where C and D are sample sets, vol is the volume in each 
sample set, and cut is the sum of the weight of the edges that 
are cut. vol and cut can be calculated via (5), (6), and (7): 
,
( ) ij
i C j V
vol C w
 
                           (5) 
,
( ) ij
i D j V
vol D w
 
                           (6) 
,
( , ) ij
i C j D
cut C D w
 
                                (7) 
To get clusters, the method needs to find the cutting place 
in the graph to minimize the value of Ncut. The resolution of 
the problem min(Ncut(C, D)) can refer to [39]. 
Figure 5 gives an example of clustering patients by using 
spectral clustering. Assume and  are patients, 
and the edges are the similarities that are obtained by the P-P 
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Matrix. By cutting the edge with the weights of 0.2 and 0.3, 
Ncut(C1, C2) can reach the minimum value. Thus, the six 
patients are separated into two clusters, and the patients in the 
same cluster have similar medication conditions. 
Generally, the patient clustering process can be described 
as follows. 
Step 1: Input the similarity matrix PJ and the number of 
clusters K. 
Step 2: Calculate the diagonal matrix D and the symmetric 
matrix of PJ. Then, obtain the Laplacian matrix L and L’, 
where L=D-A, L’=D-1/2LD-1/2. 
Step 3: Calculate the eigenvalue and eigenvector of L’: 
Ve={ve1, ve2, …, vem}. 
Step 4: Cluster patients according to the first K eigenvector 
VK={ve1, ve2, …, vek}. 
Note that in Step 1, the number of clusters is required. The 
number of clusters can be acquired by the LDA method, 
which we illustrate in section 3.3.4. In Step 4, a clustering 
method, such as K-means, is required to develop the final 
clustering result. 
The rule of acquiring Spectral Clustering is as follows: 
Rule of spectral clustering the patients: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The rule of acquiring Spectral Clustering is as follows: 
 
4) LDA MINING 
LDA [40] is a generative probabilistic model for collections 
of discrete data, such as text corpora. It is a three-level 
hierarchical Bayesian model where each item of a 
collection is modeled as a finite mixture over an underlying 
set of topics. 
LDA models have proven effective in revealing the 
mixture risk and medical behavior trends from EMRs [34]-
[41]. We propose using the LDA to calculate the similarity 
degree of each medication trace to cluster drugs into different 
groups. In EMR text mining using the LDA, the EMR text 
for a patient can be seen as a document; the name of a 
medication can be seen as a word; and the latent medication 
patterns can be seen as the topics to be discovered. However, 
in practice, physicians always use the format of <name of the 
drug: frequency in one day, duration of the days> to record 
the medication process in EMR text. Therefore, when 
sampling the name of drugs, we should label the drug name 
in each day of the medication duration. Figure 6 is the 
medication pattern discovery probabilistic graphical model 
based on LDA. 
Similar to the new document generation process in the 
LDA model, the medication (drug) generation process is as 
follows. 
Step 1: Randomly choose a distribution Φ for a medication 
pattern, where Φ is subject to a Dirichlet Distribution with 
parameter β (Φ~Dir(β)). 
Step 2: Randomly choose a distribution δ for a medication 
pattern and drug use frequency, where δ is subject to a 
Dirichlet Distribution with parameter v (δ~Dir(v)). 
Step 3: Randomly choose a distribution ρ for a medication 
pattern and drug use duration, where ρ is subject to a 
Dirichlet Distribution with parameter w (ρ~Dir(η)). 
Step 4: Randomly choose a distribution θ for a patient’s 
medication treatment D, where θ is subject to a Dirichlet 
Distribution with parameter α (θ~Dir(α)). 
Step 5: Choose D drugs by repeating the following three 
sub-steps. 
Sub-step 5-1: Probabilistically draw a medication 
pattern z from a multinomial distribution θ (z~multi(θ)). 
Sub-step 5-2: Probabilistically draw a drug use 
frequency l from δ. 
Sub-step 5-3: Probabilistically draw a drug use duration 
f from ρ. 
Based on the model and steps above, Gibbs Sampling is an 
efficient method to resolve the LDA-based problem [42], 
[43]. Following the idea of Gibbs Sampling method, we need 
to acquire p(z,w,f,l|,,v,η) and the conditional probability 
distribution of drug i over medication pattern k. This 
probability can be represented by p(zi=k|zΓi,w,f,l,,,v,η), 
where zΓi is the medication pattern distribution without drug 
i. Finally, we can get the probability of drug i over a certain 
medication pattern when Gibbs Sampling is convergent. 
According to Figure 6, we can obtain the following joint 
probability: 
 , | , , ,p z w, f,l, v      
( | ) ( | , ) ( | , , ) ( | , , )p z p w z p f w z p l w z v          (8) 
where 
( | )= ( | ) ( | )p z p z p d       
( )
,
1
1 1 1
( )1
( ) ( )
c
c
c
T C T
n
c
n
d

 

 

 
 
 
  
 

 
          (9) 
Integer k; 
 //W is a P-P Matrix 
Array W[n][n]; 
Get W[n][n]; 
Array D[n][n]; 
For i=0 to n-1 
   For j=0 to n-1 
      If i=j 
         D[i][j]=W[i][0]+W[i][1]+......+W[i][n-1]; 
      Else 
         D[i][j]=0; 
Array L[n][n]; 
For i=0 to n-1 
   For j=0 to n-1 
      L[i][j]=D[i][j]-W[i][j]; 
Array SL[n][n]; 
SL[n][n]=D[n][n]1/2L[n][n]D[n][n]1/2; 
Array F[n][m]; 
Find the m smallest eigenvalues and the 
corresponding eigenvectors of F[n][m]; 
F[n][m]=All of the eigenvectors; 
Get k clusters by K-Means(F[n][m],k) 
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in which ( ) is a Dirichlet delta function and ( )
1={ }
c C
cn n   
is the count of allocating the medication pattern c to patient  
Similarly, we can use the following equations. 
( )
1
=1
( )
( | , )= , ={ }
( )
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c c w
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p w z m r


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
              (10) 
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q c w q W Q
q c c w q
m c
v y
p l w z v y y
v v
 

 
 

  (12) 
where ( )v  , ( )v  , and ( )v v  are Dirichlet delta 
functions; ( )
1={ }
w W
c c wm m   is the count of allocating drug w to 
medication pattern c; ,
, 1{ }
w m W
m c c wx x   is the count of 
allocating drug w with using frequency m to medication 
pattern c; and ,
, 1{ }
w q W
n c c wy y   is the count of allocating drug 
w with use duration q to medication pattern c. 
Therefore, the joint probability (8) can be represented by 
(13): 
 , | , , ,p z w, f,l, v     
1 =1
( ) ( )
( ) ( )
T C
c
c
n m

 
 
   
 
   
, ,
1 =1 1 =1
( ) ( )
( ) ( )
M C M C
m c n c
m c m c
x v y
v v

 
   
 
        (13) 
According to the characteristic of the Gamma function that 
Γ(+1) = Γ(+1), we have (14): 
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 
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(14) 
Thus, the Gibbs Sampling parameters 

, 

, 

, and 

 
are acquired, and we can use these parameters to calculate 
the distribution of medication patterns. The medication 
discovery pattern is the reverse of the medication (drug) 
generation process. 
Note that the parameters of Gibbs Sampling and the 
number of clusters (namely, the number of patterns to be 
classified) should be given as input parameters when using 
the LDA-based method. Traditionally, this parameter can be 
determined by the index of perplexity [40] and the real 
medication scenario. However, some studies [44], [45] 
concluded that perplexity is not always the best way to 
determine the number of clusters, and it is sometimes slightly 
uncorrelated with human judgement. Therefore, in this 
framework, we recommend determining the number of 
clusters by using actual clinical scenarios. However, 
perplexity is also acceptable to evaluate the number of 
clusters when necessary. In IV-B-2, we give an example of 
determining the number of clusters using real scenarios. 
5) CROSS MATCHING FOR MAXIMAL PATTERN 
COVERAGE 
In the EMR text analysis process, the Spectral Clustering 
method can separate the low weight linkages between 
patients with low similarity and formulate groups of patients 
with high similarity. The LDA-based method can calculate 
the similarity degree of each medication history of patients 
and then cluster drugs into different groups of different 
medication patterns. Note that in the LDA-based method, the 
same drug may appear in different patterns with different 
memberships. As shown in Figure 7, the medication patterns 
generated by the LDA-based method may overlap, while the 
Spectral Clustering method separates patients without any 
overlap. 
As mentioned above, apart from explicitly recognizable 
differences, there are many subtle medication variances 
among different patients with similar cirrhotic ascites 
treatments. This variance has increased the medication 
complexity since physicians always use drugs with different 
functions in similar treatment episodes in practice. However, 
there are very few existing clinical pathway guidelines 
distinguishing such variances in medical processes. To 
discover those medication patterns hidden among these 
medical logs and additional clinical knowledge with less 
distinct features, we cross-matched the feature results of 
Spectral Clustering and the LDA-based methods with their 
cluster sets. This approach was inspired by multiple 
clustering related studies [46] that emphasize integrative 
clustering methods to find more stable and robust solutions 
rather than a single subset with a single algorithm with a 
single validity metric. For example, consensus clustering 
takes multiple subsets of a dataset and uses repeated 
predictions of cluster assignments to gauge stability [47]. 
HOPACH [48] recursively partitions a dataset while seeking 
to optimize a clustering measure. Both of these methods 
improve on previous single methods by repeatedly 
examining sub-clusters of a dataset. Moreover, the 
COMMUNAL method [46] proved that integrating 
information from multiple clustering algorithms and multiple 
validity measures would improve the signal and assist in 
determining stability. In other words, if the number of 
clusters is determined, cross matching on different clustering 
results may increase the focus of each cluster and enlarge the 
gap between different clusters. To let the discovered 
medication patterns represent typical clinic meanings, 
maximal coverage to represent the hidden knowledge that 
was lost in single clustering is the objective of cross 
matching, especially in complicated medication processes. 
The rules of cross matching are described as follows. 
Rules of cross matching 
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D. MEDICATION PATTERN DISCOVERY WITH TIME-
IMPORTANCE 
The results acquired by clustering lack time information 
since LDA is a word-bag-based method. To mine more 
meaningful information related to medication patterns and 
for the integrity of the framework, this section provides a 
basic method to discover more information from temporal 
sequences and evaluate the relative importance of the same 
drug in different patterns. As denoted in the P-D matrix, the 
LoSs of different patients vary, which makes measuring the 
changing drug usage in the same time scale more difficult. 
For example, a patient used drug A for 3 days during his/her 
total 3 day stay, while another patient used the same drug for 
6 days during the first days of his/her 20 day stay. How can 
we compare the drug use modes in this context? In this 
scenario, we propose a time-density-reduction method to 
evaluate the temporal drug use characteristic. In this method, 
we extended the LoSs of patients whose LoSs were shorter 
than the maximum LoS to make the medication process even. 
Following the above example, the LoS of 3 is extended to 20 
days, and he/she uses drug A, D, B, and C throughout the 20 
days all the time at the same frequencies. Figure 8 illustrates 
the time-density-reduction. In this figure, the LoS of Patient x 
is extended to the same as that of patient y. For the P-D 
matrix, the time-density-reduction is equivalent to the 
extension on the columns. 
After standardizing the LoSs of different patients to the 
same time scale, more work is required to discover 
medication characteristics according to the scenario’s needs, 
such as the drug use period of a certain patient group. Note 
that there are also negative effects in the method of time-
density-reduction. One problem is the distortion of absolute 
drug use quantity, which means that the processed data 
cannot be used for calculating or comparing the absolute 
drug use quantities of different patients. In this scenario, we 
are still able to evaluate the relative importance of drugs in 
different patterns. For example, in Figure 8, the absolute days 
of using drug D for Patient x is smaller than that of Patient y, 
whereas the stretched Patient x has a longer use period than 
Patient y. This indicates that Drug D plays a more important 
role in the treatment of Patient x than of Patient y, which we 
call the ‘time-density-reduction versus importance’ 
phenomenon. 
IV. REAL DATA ANALYSIS 
In this data experiment, we selected the patients with 
cirrhotic ascites. Ascites is the most common complication of 
cirrhosis, and 60% of patients with compensated cirrhosis 
develop ascites within 10 years during the disease’s 
progression [49], [50]. Ascites formation is the signal that the 
illness has progressed into a decompensated period that is a 
serious stage and requires treatment with medications. 
Medication for ascites always varies among patients with 
complex subtle differences with both known and unknown 
clinical knowledge. Recognizing all the medication variances 
are also an important part of the whole treatment process for 
many internal medicine diseases, and it is one of the most 
crucial components in clinical pathway guideline 
development. 
A. DATA SET AND DATA PRE-PROCESSING 
Following the above methods, we analyzed real EMR text 
from a major hospital in China. We included 998 inpatient 
EMRs from June 2014 to July 2016. All EMRs were from 
patients with hepatocirrhosis ascites, which means these 
patients have a main diagnosis of liver cirrhosis (ICD code: 
K74.151) and a secondary diagnosis of ascites (ICD code: 
R18), excluding the cases caused by hepatic carcinoma. In 
these data, we further excluded the patients who were 
transferred or dead and kept the ones that obtained effective 
treatment before being discharged from the hospital. 
The data were cleaned and anonymized before analysis, 
which means the patients’ personal information, such as 
name, age, address, and phone number, were removed. The 
//LDAClus[i][0]←patientId  
LDAClus[i][1]←meditation-pattern-Id 
Array LDAClus[][]; 
//SpectralClus[i][0]←patientId  
SpectralClus[i][1]←meditation-pattern-Id 
Array SpectralClus[][]; 
LDAClus[][]←Get data from LDA Clustering result; 
SpectralClus[][]←Get data from Spectral Clustering 
result; 
//match[i][0]←meditation-pattern-Id of LDA 
Clustering 
//match[i][1]←meditation-pattern-Id of Spectral 
Clustering 
//match[i][2]←total number of patients that 
LDAClus[x][0]=SpectralClus[y][0] 
//Assume that there are N meditation-patterns 
after clustering 
Array match[N*N][3]; 
For i=1 to |LDAClus[]| 
     where match[x][0]=LDAClus[i-1][0] and 
match[x][1]=SpectralClus[i-1][0] 
           match[x][2]++;  
//match[X1][0]∪match[X2][0]∪...∪
match[XN][0]=

1-
0
]1][[lu
N
i
isLDAC  
//match[X1][1]∪match[X2][1]∪...∪
match[XN][1]=

1-
0
]1][[lupectral
N
i
isCS  
Find 
max(match[X1][2]+match[X2][2]+...+match[XN][2]); 
Find the information of patients that belong to new 
cross matching patterns; 
Re-clustering N new meditation patterns 
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patient ID was re-coded so that it would be hard to backtrack 
the ID to the original patient but still be able to identify a 
unique patient. Figure 9 gives an example of patient ID 
obfuscation. 
Based on the masked data, we extracted the medication 
information from the text. During this process, we paid 
attention to the duration and frequency of drug use. Namely, 
the appearance of a drug name in one patient treatment 
record was in the format of frequency and duration. 
However, according to the advice of physicians in this data 
experiment, we ignored the frequency of the drug used in one 
day because the frequency is always concerned with the 
degree of the illness and the dosage of drug, which is less 
important to the clinical pathway and medication scheme. 
Thus, for each patient, the processed EMR data took the form 
of a drug list with time stamps. 
B. MEDICATION PATTERN DISCOVERY 
1) P-M MATRIX 
In this process, we first established the P-D matrix for each 
patient and calculated the similarity between different 
patients using the Jaccard Index. Figure 10 is scatter 
diagrams of the P-D matrix from real data. In Figure 10, the 
vertical axis is the drug, and each drug is coded as a number. 
The horizontal axis is the LoS, which indicates the time that 
the drug was used. 
2) LDA-BASED MEDICATION CLUSTERING 
Based on pre-processed medication data from the EMR text, 
we used the LDA-based model to extract latent medication 
patterns. Table 1 shows the patterns discovered from this 
process. In this work, parameters α, β, δ, and ρ were set to 
0.1, 0.01, 0.01, and 0.01, respectively, which are commonly 
used values in previous studies [40], [41], [51]. As for the 
number of patterns, we evaluated it from the repetition and 
representation. Figure 11 is the evaluation results of 
repetition and representation. The horizontal axis is the 
number of patterns; the left vertical axis is the representation 
degree; and the right vertical axis is the repetition. The dotted 
line represents repetition, and the solid line is representation. 
Repetition reflects the ratio of drugs that repetitiously appear 
in different clusters to the total drugs that in all patterns. The 
higher the value, the more overlap among different clusters. 
The treatments for cirrhotic ascites are similar. According to 
the physician’s advice, the number of patterns should be as 
small as possible. Figure 11 indicates that the repetition value 
is similar when the pattern number is in the range of 3 to 10. 
If the number of patterns continues to decrease, the repetition 
rapidly rises. Therefore, three patterns are an optimal solution 
in this context. Moreover, the representation data indicate 
that the drugs in the patterns are more representative than 
other cases when there are three patterns. Thus, we selected 3 
as the number of patterns. 
In the LDA-based method, a patient can belong to 
different clusters with different memberships. This is the 
point that we mentioned at the beginning of the paper: some 
methods are difficult to cluster the patients with subtle 
treatment variances under similar symptoms. In this case, we 
first clustered them into the different patterns according to 
their highest membership. Then, in the following steps, we 
performed cross matching to ensure that the distinct 
characteristics of the medications among different patients 
were focused. The cross-matching results are given in the 
next section. 
Figure 12 shows the results of the LDA-based patient 
clusters. The round is composed by all patient IDs. Each line 
establishes the similarity link between two patients, and the 
lines in different colors indicate the cluster to which a patient 
belongs. 
Figure 13 is the fingerprint map of the LDA-based patient 
cluster. The three bars demonstrate the patients clustering 
results acquired by the pure LDA method. We clustered the 
patients into three groups. The dark blocks indicate a high 
membership weight of the corresponding cluster to which a 
patient belongs, while the light blocks represent a low 
membership weight. The patients are sequenced by ID on the 
horizontal axis. 
3) SPECTRAL CLUSTERING 
Based on the P-M matrix, we calculated the Jaccard 
similarity index and acquired the P-P matrix. Since the 
matrix was huge, we displayed the matrix using a heat map, 
as shown in Figure 14. In this figure, the deep colors 
represent weak similarity, and the light colors represent 
strong similarity. 
According to the P-P matrix and the evaluation of cluster 
numbers above, we clustered the patients into 3 groups using 
the Spectral Clustering method as shown in Figure 15. 
4) CROSS MATCHING AND MEDICATION PATTERNS 
Based on the data processing result in section 4.2.1 and the 
initial clustering results in 4.2.2 and 4.2.3, we cross-matched 
the features and clustering sets between the Spectral and 
LDA-based clustering methods to acquire the medication 
patterns, as shown in Table 1. We used two different 
methods to acquire the Spectral Clustering results. One 
method was K-means (KM) based, and the other method was 
the discretize (DIS)-based method. According to the results, 
the two approaches yielded similar results. Therefore, in the 
following discussion, we only used the results from the K-
means-based method marked with gray shading in Table 1. 
As shown in the table, we acquired three medication patterns 
with focused clinical meanings and discovered a previously 
unexplored mixed pattern. Technically, the mixed pattern 
represents the datasets that are only covered by one 
clustering method (either LDA or spectral) and represents the 
residual knowledge, as shown in white areas of Figure 7. 
From a clinical point of view, the patients with relatively 
complex diseases require treatment with more combinations 
of various drugs. For these patients, the medication treatment 
patterns are vague and difficult to be classified into the above 
patterns. Note that in most of the current methods, all of the 
sample patients are classified into one specific group. 
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Although this might be possible from the view of data 
mining, the clinical meaning for each cluster is not always 
clear. Our method outperforms existing methods in 
identifying major distinct patterns and mixed patterns. In 
Table 1, the names of drugs are marked with different 
symbols to indicate the clinical functions. Clinical functions 
are an important clue to identify the clinical meaning of each 
medication pattern. The discovered medication patterns 
represent drugs that provide liver protection, have antiviral 
activity, and ease ascites. The drug in each pattern is listed by 
the sequence of the use probability. 
5) MEDICATION PATTERNS WITH TIME-SEQUENTIAL 
CHARACTERISTICS 
Following the medication pattern discovery, we analyzed the 
time characters in these patterns. Based on the time-density-
reduction method, we divided the LoS of each patient into 40 
segments and calculated the medication process based on the 
discovered patterns. For example, the medication process of 
a patient with a 20-day-LoS will be divided into 40 pieces 
since 0.5 day is the calculation unit. Figure 15 to Figure 17 
show the medication conditions for each pattern with time 
characteristics. The vertical axis indicates the percentage of 
patients in the corresponding pattern. The patient number 
here is not the absolute amount but is amplified by the time-
density-reduction method. 
As noted above, due to the time-density-reduction method, 
some drugs that appear in Figures 16-18 were not included in 
the patterns in Table 1. According to the ‘time-density-
reduction versus importance’ phenomenon, these drugs are 
the drugs often used by patients with short LoSs. For 
instance, in Figure 16, Spironolactone Tablets are the drug 
used by most of the amplified patients (patients with 
extended LoSs). However, Spironolactone is not included in 
medication Pattern 1 in Table 1. Therefore, we concluded 
that most of the patients who belong to Pattern 1 and are 
given Spironolactone Tablets have short LoSs, and this 
medicine is more important for patients in Pattern 1. 
According to the medication characteristics in each 
pattern, we chose 6 typical drugs (Furosemide Tablets, 
Furosemide Injection, Ursofalk Capsule, Leucogen Tablets, 
Insulin R Injection, and Coenzyme Complex for Injection) to 
further analyze the medication patterns. The reason for 
selecting these 6 drugs is that they appeared in more than one 
pattern, and all of them have high usage probabilities. 
Figures 19 through 23 show the analysis results where the 
vertical axis represents the proportion of patients using the 
corresponding drug, and the horizontal axis represents the 
unified LoSs (which can be understood as timing sequences). 
Figure 19 and Figure 20 are both the usage characteristics 
of Furosemide, which is a diuretic drug. Figure 19 shows the 
results of Furosemide Tablets, and Figure 20 shows 
Furosemide Injections. In Figure 19, the drug usage 
characteristics are similar, but minor differences exist in the 
different patterns. In Figure 20, significant differences appear 
among the patterns. The proportions of patients who use 
Furosemide Injections in Pattern 1 and Pattern 2 are higher 
than those in Pattern 3. Furosemide is a diuretic drug, but 
patients who need the treatment to alleviate ascites use less 
Furosemide. One reasonable explanation is that Furosemide 
Injections are stronger than Furosemide Tablets. Therefore, 
the Furosemide Injection is always used as a short-term and 
effective medication treatment for patients without serious 
ascites. Furthermore, the patients with serious ascites take 
Furosemide Tablets for long-term and surgical treatments. 
Figure 21 illustrates the drug use characteristics of the 
Coenzyme Complex for Injections. Clearly, huge differences 
exist in these patterns. The high usage proportion indicates 
that the Coenzyme Complex for Injections is a very 
important drug for the patients in Pattern 2. According to the 
function of the Coenzyme Complex for Injections, it is 
mainly used for curing hepatitis, and the results in Figure 21 
are completely consistent with the clinical meaning of Pattern 
2. 
Figure 22 and Figure 23 show the drug usage of Leucogen 
Tablets and Insulin R Injections. Both of them are commonly 
used for patients with cirrhotic ascites, especially for 
complications during the medication treatment. These results 
reveal that Leucogen Tablets are more important in Pattern 1 
and Pattern 2, and Insulin R Injections are more important for 
patients in Pattern 3, especially in the middle and later 
treatment periods. 
6) EVALUATION OF THE MEDICATION PATTERN 
DISCOVERING FRAMEWORK 
Based on the experiment above, we evaluated the patterns 
discovered from the EMR text using the proposed 
framework. Figure 24 is the comparison of the performances 
of different medication mining methods. The bars in this 
figure are the clustering results acquired by the pure LDA, 
pure Spectral Clustering, and the proposed frameworks, 
respectively. We used light green, dark green and black 
blocks to represent the patients in Pattern 1, Pattern 2, and 
Pattern 3, respectively. The patients are sequenced by their 
IDs on the horizontal axis. The first bar represents the LDA 
clustering results based on the membership weight shown in 
Figure 13. The second bar shows the results of Spectral 
Clustering. The last one shows the results of our proposed 
method in which the white blocks represent the patients 
filtered by cross matching the features and clustering sets 
between the Spectral and LDA methods. Obviously, 
approximately half of the patients have similar memberships 
in different clusters, which are difficult to separate. Cross 
matching plays an important role in filtering the confusing 
items from the whole data set. 
The key goal of the proposed method was to discover 
medication patterns. Figure 25 and Figure 26 are the 
comparisons of the drugs from different patterns acquired by 
the LDA and proposed methods. In these two figures, we 
classified the drugs into four function groups represented by 
different color blocks. Those groups represent liver 
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protection (yellow, one star in Table 1), antiviral (red, two stars in Table 1), ascites treatment (blue, three stars in Table 
1), and other functions (white, no star in Table 1). For the 
patterns discovered by the pure LDA methods in Figure 25, 
we see that it is difficult to distinguish the functional patterns. 
All three patterns have high probabilities to use the drugs that 
function to protect the liver. This indicates that the 
characteristics of the patterns are not distinct and obvious. In 
the results acquired by the new proposed method in Figure 
26, each discovered medication pattern has a distinct focus 
on drug functions, starting with different color blocks. The 
starting blocks indicate the drug function with the highest use 
probability in the corresponding pattern. By using cross 
matching, some medication treatments with similar drug use 
are separated. We further analyzed these patients and 
acquired the distribution of drug use probability shown as the 
last three bars in Figure 26. The filtered medications have 
mixed drug use conditions. 
V. DISCUSSION AND CONCLUSIONS 
Based on the real EMR textual data from patients with 
cirrhotic ascites, we proposed a medication pattern discovery 
framework to help physicians make clinical decisions based 
on medication patterns. This study effectively identified the 
medication patterns from EMRs, especially for diseases with 
minor treatment variances from complex medication 
treatments. For example, ascites cirrhosis is a common 
disease, but the clinical practice guidelines released by EASL 
(European Association for the Study of the Liver) [49] are 
different from AASLD (American Association for the Study 
of Liver Diseases) [52]. Both of these associations give 
professional and official clinical guidelines in their respective 
regional area. The question is which one performs better for 
which groups of patients. Regardless of the type of illness, 
similar questions also arise among different hospitals and 
physicians. Every hospital may have its own specific clinical 
guidelines or clinical pathways based on authoritative 
doctors. Moreover, each physician probably has his/her own 
clinical treatment style under the guideline. In consideration 
of those variances, in recent years, physicians and researchers 
have increasingly focused on personalized pathways to 
acquire better curative effects [53], [54]. Physicians 
acknowledge the importance of standard or reference clinical 
pathways, but they also argue that more attention should be 
paid to the most suitable treatment for a specific patient 
rather than a universal standard. 
Current existing methods can hardly classify the latent 
drug use patterns in the above scenarios. The proposed 
method is based on the Jaccard index, Spectral Clustering 
and modified LDA method. By cross matching, the clustered 
results are well focused on the specific medication patterns 
with little overlap. This framework filters some medication 
treatments with high mixed drug usage and then clusters 
them into a distinct single group. It is different from the 
current methods in which all sampling data have to be 
classified into one certain group. 
Mining medication treatment patterns is helpful in the 
process of predicting clinical history, and medication 
treatments are an important component in clinical pathway 
development. In the ongoing and following future work, we 
plan to address the following. 1) We may introduce more 
types of data into the clustering process, such as the 
examination results during the LoS, which can evaluate the 
effects of corresponding medication processes and mine the 
best-fit treatment pattern for corresponding patient groups. 2) 
In this paper, we only consider the medications in the 
treatment process. In the future, we will consider more kinds 
of treatment contents, such as clinical examinations, bedside 
operations, and even nursing contents. These contents are all 
necessary components of the clinical pathway. 3) We are 
working on a clinical decision support system that integrates 
the methods that we have developed. The input data of this 
system is EMR text, and the outcomes are the medication 
knowledge hidden in the EMR text. We performed initial 
work (as shown in Figure 27) based on the proposed method 
in this paper. One specific format of the decision support 
system is that a facility needs to be able to automatically 
recommend clinical pathways with corresponding analyzed 
data and confidence degrees based on the imported EMR 
data. 
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